101 related articles for article (PubMed ID: 33628047)
1. In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Fleisher B; Lezeau J; Werkman C; Jacobs B; Ait-Oudhia S
Breast Cancer (Dove Med Press); 2021; 13():87-105. PubMed ID: 33628047
[TBL] [Abstract][Full Text] [Related]
2.
Mody H; Vaidya TR; Lezeau J; Taha K; Ait-Oudhia S
Front Pharmacol; 2023; 14():1239141. PubMed ID: 37927589
[TBL] [Abstract][Full Text] [Related]
3. Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review.
Martorana F; Sanò MV; Valerio MR; Fogli S; Vigneri P; Danesi R; Gebbia V
Ther Adv Drug Saf; 2024; 15():20420986231224214. PubMed ID: 38665218
[TBL] [Abstract][Full Text] [Related]
4. Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model.
García-Castillo V; López-Urrutia E; Villanueva-Sánchez O; Ávila-Rodríguez MÁ; Zentella-Dehesa A; Cortés-González C; López-Camarillo C; Jacobo-Herrera NJ; Pérez-Plasencia C
J Cancer; 2017; 8(2):178-189. PubMed ID: 28243322
[No Abstract] [Full Text] [Related]
5. Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells.
Naba NM; Tolay N; Erman B; Sayi Yazgan A
Turk J Biol; 2020; 44(1):15-23. PubMed ID: 32123492
[TBL] [Abstract][Full Text] [Related]
6. DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis.
Cao S; Long X; Xiao L; Zhang P; Shen M; Chen F; Bao C; Zhong X; Luo T; Ye F
Front Oncol; 2024; 14():1356778. PubMed ID: 38549944
[TBL] [Abstract][Full Text] [Related]
7. Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin.
Pusuluri A; Krishnan V; Wu D; Shields CW; Wang LW; Mitragotri S
Bioeng Transl Med; 2019 May; 4(2):e10129. PubMed ID: 31249879
[TBL] [Abstract][Full Text] [Related]
8. Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer.
Zeng W; Luo Y; Gan D; Zhang Y; Deng H; Liu G
Front Bioeng Biotechnol; 2023; 11():1271420. PubMed ID: 38047286
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer.
Berry JTL; Muñoz LE; Rodríguez Stewart RM; Selvaraj P; Mainou BA
Mol Ther Oncolytics; 2020 Sep; 18():556-572. PubMed ID: 32995480
[TBL] [Abstract][Full Text] [Related]
10. Phenotypically Screened Carbon Nanoparticles for Enhanced Combinatorial Therapy in Triple Negative Breast Cancer.
Kampert T; Misra SK; Srivastava I; Tripathi I; Pan D
Cell Mol Bioeng; 2017 Oct; 10(5):371-386. PubMed ID: 31719869
[TBL] [Abstract][Full Text] [Related]
11. Lysine-Polydopamine Nanocrystals Loaded with the Codrug Abemaciclib-Flurbiprofen for Oral Treatment of Cancer.
Sun T; Zhang F; Xu Y; Wang X; Jia J; Sang L; Li J; Wang D; Yu Z
ACS Omega; 2024 Apr; 9(16):18137-18147. PubMed ID: 38680297
[TBL] [Abstract][Full Text] [Related]
12. A Novel Figure and Algorithm for the Gold ABE Classification.
Miravitlles M; Kostikas K; Bizymi N; Tzanakis N
Arch Bronconeumol; 2023 Nov; 59(11):702-704. PubMed ID: 37355409
[No Abstract] [Full Text] [Related]
13. A Novel Figure and Algorithm for the GOLD-ABE Classification: Additional Comments.
Golpe R; Figueira-Gonçalves JM; Esteban C; Amado CA; Dacal-Rivas D; Veiga I
Arch Bronconeumol; 2023 Dec; 59(12):846-847. PubMed ID: 37827950
[No Abstract] [Full Text] [Related]
14. Curcumin Rescues Doxorubicin Responsiveness via Regulating Aurora a Signaling Network in Breast Cancer Cells.
Biswas S; Mahapatra E; Ghosh A; Das S; Roy M; Mukherjee S
Asian Pac J Cancer Prev; 2021 Mar; 22(3):957-970. PubMed ID: 33773562
[TBL] [Abstract][Full Text] [Related]
15. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
[TBL] [Abstract][Full Text] [Related]
16. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract][Full Text] [Related]
17. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III.
Witkowski J; Polak S; Pawelec D; Rogulski Z
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768563
[TBL] [Abstract][Full Text] [Related]
18. Light-Enhanced Cytotoxicity of Doxorubicin by Photoactivation.
Greco G; Ulfo L; Turrini E; Marconi A; Costantini PE; Marforio TD; Mattioli EJ; Di Giosia M; Danielli A; Fimognari C; Calvaresi M
Cells; 2023 Jan; 12(3):. PubMed ID: 36766734
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin.
Mody H; Vaidya TR; Lesko LJ; Ait-Oudhia S
Cells; 2022 Dec; 12(1):. PubMed ID: 36611850
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
